TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22982353
Drug: Oral contraceptive
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptive (OC) containing levonorgestrel and EE (150/30 μg)
Study: 19383221
Drug: Valsartan/hydrochlorothiazide 80
Normalized name: valsartan/hydrochlorothiazide 80 mg-12.5 mg ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan/hydrochlorothiazide 80 mg/12.5 mg once daily
Study: 24127952
Drug: No therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: No therapy or placebo
Study: 9717596
Drug: 4 ml
Normalized name: ethanol 1.4 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 ml lidocaine 1%
Study: 9717596
Drug: 6 ml
Normalized name: ethanol 0.6 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 ml lidocaine 1%
Study: 9717596
Drug: 8 ml
Normalized name: ethanol 0.8 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 ml lidocaine 1%
Study: 8122656
Drug: Ketoconazole 200
Normalized name: ketoconazole 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoconazole 200 mg/day p.o.
Study: 8122656
Drug: Fluconazole 50
Normalized name: fluconazole 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluconazole 50 mg/day p.o.
Study: 15487320
Drug: No antifungal
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antifungal therapy
Study: 2549204
Drug: 500 mg/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg/m2 as a continuous intravenous (IV) infusion over 24 hours
Study: 2549204
Drug: Five consecutive
Normalized name: fivehorn smotherweed pollen extract
DrugBank: Bassia hyssopifolia pollen (DB10941)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Five consecutive daily 2-hour infusions each of 100 mg/m2
Study: 16960528
Drug: Rabeprazole (RAB)
DrugBank: Rabeprazole (DB01129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rabeprazole (RAB) 20 mg x d(‐1)
Study: 16960528
Drug: Sham esophageal
Normalized name: Cellspan Esophageal Implant
DrugBank: Cellspan Esophageal Implant (DB18688)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham esophageal infusion (NG tube placed in the distal esophagus, no fluid)
Study: 8471132
Drug: Debrisoquin (DBQ),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Debrisoquin (DBQ), an inhibitor of monoamine oxidase
Study: 6342335
Drug: Cimetidine 800
Normalized name: cimetidine 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 800 mg daily
Study: 3520794
Drug: Cimetidine 1600
Normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cimetidine 1600 mg daily
Study: 3520794
Drug: Cimetidine 400
Normalized name: cimetidine 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 400 mg single-dose maintenance treatment
Study: 29503145
Drug: Supplementation with
Normalized name: Similac For Supplementation with Iron Powder for Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplementation with fish oil (1.7 g EPA + DHA/day), chocolate containing plant sterols (2.2 g/day), and green tea (two sachets/day) for 6 weeks
Study: 29503145
Drug: Statin dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin dose reduction by 50% from weeks 6-12 after 6 weeks of standard therapy
Study: 25352050
Drug: Tuina massage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tuina massage therapy (20 minutes, 4-step treatment protocol, 20 sessions over 4 weeks)
Study: 25352050
Drug: Conventional analgesics
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional analgesics (specific daily dose of ibuprofen)
Study: 20942292
Drug: Tuina massage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tuina massage therapy
Study: 20738314
Drug: Physiological sex
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physiological sex steroid replacement (pSSR)
Study: 22343553
Drug: Standard sex
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard sex steroid replacement (sSSR)
Study: 17112304
Drug: Rimonabant 20mg
Normalized name: rimonabant
DrugBank: Rimonabant (DB06155)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Rimonabant 20mg once daily
Study: 7286051
Drug: Chlorthalidone 50
Normalized name: chlorthalidone 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorthalidone 50 mg
Study: 8862940
Drug: Chlorthalidone 50
Normalized name: chlorthalidone 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorthalidone 50 mg/triamterene 50 mg combination treatment
Study: 1736500
Drug: Low-dose diethylstilbestrol
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose diethylstilbestrol (DES) 1 mg daily
Study: 6225627
Drug: 5 percent
Normalized name: LIDOCAINE 5 g in 100 g TOPICAL CREAM [Lidocaine 5 Percent]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 percent benzoyl peroxide acetone gel for four weeks
Study: 6225627
Drug: 10 percent
Normalized name: BENZOYL PEROXIDE 10 g in 100 mL TOPICAL LOTION [SMART RELEASE BPO 10 PERCENT]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 percent benzoyl peroxide acetone gel for an additional four weeks
Study: 6225627
Drug: Placebo (acetone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (acetone gel vehicle)
Study: 140786
Drug: Benzoyl peroxide
Normalized name: Benzoyl Peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Benzoyl peroxide acetone gel
Study: 30131297
Drug: Inhaled vancomycin
Normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inhaled vancomycin
Study: 29712666
Drug: Oral vitamin
Normalized name: vitamin A Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral vitamin D3 (100,000 IU or 12,000 IU, n = 31 each) administered once monthly for 2 years
Study: 29712666
Drug: Oral vitamin
Normalized name: vitamin A Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral vitamin D3 (standard dose 12,000 IU) administered once monthly for 2 years
Study: 27271717
Drug: Local cement
Normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local cement reinforcing antibacterial implant
Study: 17398307
Drug: Methylprednisolone 20
Normalized name: methylprednisolone 2000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone 20 mg intravenously, started 12 hours before extubation and every 4 hours until tube removal
Study: 17398307
Drug: Methylprednisolone 20
Normalized name: methylprednisolone 2000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone 20 mg intravenously
Study: 16142596
Drug: Captopril 12.5
Normalized name: captopril 12.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril 12.5 mg administered at night
Study: 16142596
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered at night
Study: 12142389
Drug: Aromatase inhibitor
Normalized name: Aromatase inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aromatase inhibitor (fadrozole)
Study: 2288051
Drug: Ciprofloxacin 100
Normalized name: ciprofloxacin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin 100 mg orally, twice a day for 4 days
Study: 2288051
Drug: Ciprofloxacin 500
Normalized name: ciprofloxacin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin 500 mg orally, twice a day for 4 days
Study: 7293935
Drug: Amino acid
Normalized name: Amino Acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amino acid preparation
Study: 29967411
Drug: Placebo group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo group (inactive treatment)
Study: 23210068
Drug: Midazolam-dexamethasone (0.075
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam-dexamethasone (0.075 mg/kg + 0.05 mg/kg)
Study: 7889885
Drug: Boron supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Boron supplementation (2.5 mg for 7 weeks)
Study: 3300457
Drug: Propranolol (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (80 to 240 mg twice a day)
Study: 3300457
Drug: Diltiazem (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem (60 to 180 mg twice a day)
Study: 3300457
Drug: Propranolol with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol with Hydrochlorothiazide (for patients not achieving treatment goal)
Study: 26537941
Drug: Lipid-based nutrient
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipid-based nutrient supplements (LNSs) with antiretrovirals
Study: 22017782
Drug: Naproxen 275
Normalized name: naproxen sodium 275 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen 275 mg every 12 hours for 120 hours
Study: 22017782
Drug: Placebo 275
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 275 mg every 12 hours for 120 hours
Study: 17634178
Drug: Lingual 24%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lingual 24% sucrose (0.5-2 ml varying with body weight) administered 2 min before nasogastric tube insertion
Study: 17634178
Drug: Water placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water placebo (0.5-2 ml varying with body weight) administered 2 min before nasogastric tube insertion
Study: 12871445
Drug: Bemiparin (3500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bemiparin (3500 IU anti-factor Xa, first dose 6 h after surgery)
Study: 12871445
Drug: Enoxaparin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin (40 mg, first dose 12 h before surgery)
Study: 28363933
Drug: Melatonin 0.5
Normalized name: melatonin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin 0.5 mg
Study: 10594526
Drug: Melatonin 5.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin 5.0 mg
Study: 392853
Drug: L-lysine monohydrochloride,
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-lysine monohydrochloride, 1,000 mg daily for five days
Study: 25822924
Drug: Nebulized ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized ketamine (2 mg/kg)
Study: 25822924
Drug: Nebulized dexmedetomidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized dexmedetomidine (2 μg/kg)
Study: 25822924
Drug: Combined nebulized
Normalized name: Hydra-Neb
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined nebulized dexmedetomidine and ketamine (1 μg/kg + 1 mg/kg)
Study: 23818535
Drug: Usual treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual treatment alone (Control)
Study: 21114602
Drug: 12 Oral-lyn
Normalized name: Pediatex 12 Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 Oral-lyn puffs (1 puff = 1 s.c. rapid insulin UI), split into two doses before and after OGTT
Study: 21114602
Drug: 6 Oral-lyn
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 Oral-lyn puffs (used in group C)
Study: 19182178
Drug: Social activity
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Social activity therapy (SAT)
Study: 17483968
Drug: 0.1% isotretinoin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% isotretinoin gel for 4 months
Study: 9579836
Drug: PBPC+G‐CSF (n
Approvals — FDA: no, EMA: no, PMDA: no
Description: PBPC+G‐CSF (n = 11)
Study: 8043974
Drug: Low-dose prednisolone
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose prednisolone (0.5 mg/kgBW daily for 1 week, then tapered by 0.1 mg/kg BW/week for 1 month) and chlorambucil (0.12 mg/kgBW daily) administered during months 1-6.
Study: 8043974
Drug: Low-dose prednisolone
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose prednisolone and chlorambucil therapy
Study: 3052785
Drug: Metoclopramide (MCP)
DrugBank: Metoclopramide (DB01233)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metoclopramide (MCP) alone (total dose, 6 mg/kg)
Study: 3052785
Drug: Metoclopramide (MCP)
DrugBank: Metoclopramide (DB01233)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metoclopramide (MCP) plus Dexamethasone (DMS) (total dose, 60 mg)
Study: 30500309
Drug: Five weekly
Normalized name: fivehorn smotherweed pollen extract
DrugBank: Bassia hyssopifolia pollen (DB10941)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Five weekly cellphone-delivered sessions of stigma and alcohol-enhanced behavioural self-regulation counselling
Study: 25522265
Drug: Broccoli sprouts
Normalized name: broccoli sprout extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Broccoli sprouts (200 μmol SFN daily)
Study: 25522265
Drug: Myrosinase-treated broccoli
Approvals — FDA: no, EMA: no, PMDA: no
Description: Myrosinase-treated broccoli sprout extract (BSE) (200 μmol SFN daily)
Study: 25522265
Drug: Twice daily
Normalized name: CAPSULE, TWICE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice daily dosing (two 100-μmol doses taken 12 h apart)
Study: 25522265
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose (200 μmol SFN)
Study: 20929915
Drug: Intravenous ferric
Normalized name: Ferric Oxide
DrugBank: Ferric oxide (DB11576)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous ferric carboxymaltose 1000 mg over 15 min (with up to two additional doses of 500 mg at 2-week intervals)
Study: 20929915
Drug: Intravenous ferric
Normalized name: Ferric Oxide
DrugBank: Ferric oxide (DB11576)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous ferric carboxymaltose 1000 mg over 15 min
Study: 20929915
Drug: Oral ferrous
Normalized name: ferrous fumarate Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ferrous sulphate 325 mg thrice daily for a total of 195 mg elemental iron daily for 56 days
Study: 18236203
Drug: 8-week treatment
Normalized name: Weeks and Leo Complete Lice Treatment KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8-week treatment group (n = 10)
Study: 9532649
Drug: Ascolong (12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ascolong (12.5 mg) administered once or regularly for 2 weeks
Study: 9532649
Drug: Ascolong (12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ascolong (12.5 mg)
Study: 8057111
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose levodopa-carbidopa (<= 600/150 mg/day)
Study: 8057111
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose bromocriptine (<= 30 mg/day)
Study: 2970159
Drug: 1% clindamycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% clindamycin phosphate in alcoholic solution
Study: 28150367
Drug: 5% benzoyl
Normalized name: BENZOYL PEROXIDE 2.5 g in 100 mL TOPICAL SOAP [Benzoyl Acne Wash -2.5% Benzoyl Peroxide]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% benzoyl peroxide gel
Study: 26699542
Drug: Chinese Herbal
Normalized name: GINGER 28 mg in 100 mL TOPICAL OIL [Pain Relief Honzo Seika Chinese Herbal Aroma Oil]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese Herbal Medicine (CHM)
Study: 26699542
Drug: Non-Chinese Herbal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-Chinese Herbal Medicine (non-CHM)
Study: 23152361
Drug: Irsogladine maleate
Normalized name: maleate
DrugBank: Irsogladine (DB13056)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irsogladine maleate (IM) 4 mg/day for 14 days
Study: 19189989
Drug: Hormone replacement
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone replacement therapy (HRT) - Tibolone (n = 25)
Study: 10904853
Drug: Treatment according
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment according to the etiology of the disease (specific treatment not detailed in the abstract)
Study: 10904853
Drug: Placebo (not
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (not explicitly mentioned but implied as part of the American Myocarditis Treatment Trial)
Study: 9488974
Drug: Zidovudine or
Normalized name: zidovudine Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zidovudine or didanosine before and after treatment
Study: 7870965
Drug: Cocaine administered
Normalized name: Cocaine
DrugBank: Cocaine (DB00907)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocaine administered alone (4-96 mg/70 kg)
Study: 7870965
Drug: Alcohol administered
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alcohol administered alone (0-1.0 g/kg)
Study: 25887111
Drug: Ramelteon 8
Normalized name: ramelteon 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramelteon 8 mg before bedtime for 4 weeks
Study: 22925428
Drug: Reimbursement for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reimbursement for smoking cessation treatment
Study: 15948996
Drug: Oral pimecrolimus
Normalized name: Pimecrolimus
DrugBank: Pimecrolimus (DB00337)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral pimecrolimus 30 mg twice daily
Study: 15948996
Drug: Oral pimecrolimus
Normalized name: Pimecrolimus
DrugBank: Pimecrolimus (DB00337)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral pimecrolimus 20 mg twice daily
Study: 15948996
Drug: Oral pimecrolimus
Normalized name: Pimecrolimus
DrugBank: Pimecrolimus (DB00337)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral pimecrolimus 10 mg twice daily
Study: 10888946
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment (frequently repeated active submaximal movements combined with mechanical diagnosis and therapy)
Study: 10888946
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment (early administration within 96 hours)
Study: 10888946
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (initial rest, recommended use of a soft collar, gradual self-mobilization)
Study: 1416808
Drug: Valproate (VPA),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valproate (VPA), 15 mg/kg
Study: 1416808
Drug: Felbamate (FBM),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Felbamate (FBM), 3,600 mg/day
Study: 29496255
Drug: Tivantinib (360
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tivantinib (360 mg twice daily) plus Erlotinib (150 mg daily)
Study: 29496255
Drug: Single-agent chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-agent chemotherapy (investigator's choice of pemetrexed, docetaxel, or gemcitabine)
Study: 29496255
Drug: Single-agent chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-agent chemotherapy (C)
Study: 18632218
Drug: Oral visual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral visual inspection intervention
Study: 12192164
Drug: Antimicrobial therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antimicrobial therapy (various types)
Study: 7924477
Drug: Disodium cromoglycate
Normalized name: Disodium cromoglycate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disodium cromoglycate (DSCG), 40 mg
Study: 31895776
Drug: Traditional Chinese
Normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional Chinese Medicine (TCM) individualized treatment
Study: 21633535
Drug: Water infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water infusion limited to the rectum, sigmoid colon and descending colon
Study: 16738289
Drug: Vecuronium 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vecuronium 0.1 mg.kg(‐1) iv
Study: 15537991
Drug: Task-oriented physical
Normalized name: Oriental melon
DrugBank: Muskmelon (DB15611)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Task-oriented physical therapy with rehabilitation technology (treadmill, Kinetron isokinetic exerciser, limb-load monitor)
Study: 15537991
Drug: Task-oriented physical
Normalized name: Oriental melon
DrugBank: Muskmelon (DB15611)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Task-oriented physical therapy without rehabilitation technology
Study: 15537991
Drug: Task-oriented physical
Normalized name: Oriental melon
DrugBank: Muskmelon (DB15611)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Task-oriented physical therapy (both groups pooled)
Study: 6362385
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment (crossover group)
Study: 6362385
Drug: Medical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical treatment (medical adherers group)
Study: 27632557
Drug: Rupatadine 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rupatadine 40 mg
Study: 27632557
Drug: Rupatadine (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rupatadine (all doses)
Study: 22295891
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil supplement (2 g containing 600 mg EPA and DHA) for 9 weeks
Study: 17913001
Drug: CPC/ZG mucoadhesive
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPC/ZG mucoadhesive gel
Study: 17241421
Drug: UV-B irradiation
Normalized name: Influenza B virus B/Brisbane/60/2008 antigen (UV, formaldehyde inactivated)
Approvals — FDA: no, EMA: no, PMDA: no
Description: UV-B irradiation after BoNT/A injection
Study: 17241421
Drug: BoNT/A injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: BoNT/A injection (100 mU)
Study: 10926345
Drug: Salmeterol/fluticasone propionate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmeterol/fluticasone propionate combination therapy 50/250 microg twice daily
Study: 1600111
Drug: Syrup formulations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Syrup formulations
Study: 1600111
Drug: Capsule formulations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule formulations
Study: 1600111
Drug: Both dosage
Normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both dosage forms
Study: 24641586
Drug: Cholecalciferol treatment
Normalized name: Cholecalciferol
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholecalciferol treatment
Study: 28929919
Drug: Functional electrical
Normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Functional electrical stimulation therapy assisted walking (FES‐T)
Study: 24092833
Drug: Oral vitamin
Normalized name: vitamin A Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral vitamin D₃ 4000 IU/d
Study: 24092833
Drug: Oral vitamin
Normalized name: vitamin A Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral vitamin D₃ 400 IU/d
Study: 24092833
Drug: Oral vitamin
Normalized name: vitamin A Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral vitamin D₃ (all doses)
Study: 16140508
Drug: One-Stage group
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: One-Stage group (n=32) received 12 months of inpatient treatment
Study: 16140508
Drug: Step-Down group
Normalized name: Kool-Down
Approvals — FDA: no, EMA: no, PMDA: no
Description: Step-Down group (n=29) received 6 months of inpatient treatment followed by 12 months of outpatient therapy